Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026677 | 0.75 | HTT (0.42) | ACACB | |
| SCHEMBL20863049 | 0.73 | EPHX1 (0.33) | ACACB | |
| SCHEMBL15338880 | 0.72 | POLB (0.44) | ACACB | |
| SCHEMBL19009022 | 0.68 | — | — | |
| SCHEMBL23893056 | 0.66 | — | — | |
| SCHEMBL19026686 | 0.66 | — | — | |
| SCHEMBL18769088 | 0.66 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL31446809 | 0.63 | ACACB (0.40) | ACACB | |
| SCHEMBL19000045 | 0.63 | ACACB (0.42) | ACACB | |
| SCHEMBL30988285 | 0.63 | ALDH1A1 (0.39) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | ACACB 1411/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | ACACB 1411/4885 |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | ACACB 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.